Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Canaccord Genuity maintained a Buy rating on Verona Pharma (NASDAQ:VRNA) while significantly increasing the price target to $72.00 from the previous $44.00. According to InvestingPro data, analyst ...

Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler prescribed for COPD and asthma. Trelegy Ellipta has interactions with some other drugs ...

For instance, the approval of Verona Pharma’s Ohtuvayre by the U.S. Food and Drug Administration (FDA) provided a much-needed non-steroid inhaled treatment option for patients with chronic obstructive ...

Verona's stock could build on its gains from last year depending on how well the rollout of Ohtuvayre goes. And if the company is able to shrink its losses (they have totaled $154 million over the ...

Verona Murphy spent her first full day in the Dáil this week and had her work cut out for her as tension rose, causing her to suspend the meeting twice. Failing to pass the position of Taoiseach back ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...